Downloads: 281

Files in This Item:
File Description SizeFormat 
s00280-009-1239-7.pdf189.36 kBAdobe PDFView/Open
Title: Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer.
Authors: Yanagihara, Kazuhiro
Yoshimura, Kenichi
Niimi, Miyuki
Yasuda, Hiroyasu
Sasaki, Takahiko
Nishimura, Takafumi
Ishiguro, Hiroshi  kyouindb  KAKEN_id
Matsumoto, Shigemi  kyouindb  KAKEN_id
Kitano, Toshiyuki  kyouindb  KAKEN_id
Kanai, Masashi  kyouindb  KAKEN_id
Misawa, Akiko
Tada, Harue  kyouindb  KAKEN_id
Teramukai, Satoshi
Mio, Tadashi
Fukushima, Masanori
Author's alias: 柳原, 一広
Keywords: Non-small cell lung cancer
Phase II study
Docetaxel
S-1
Second-line chemotherapy
Third-line chemotherapy
Issue Date: Oct-2010
Publisher: Springer-Verlag
Citation: AA00598397
Journal title: Cancer chemotherapy and pharmacology
Volume: 66
Issue: 5
Start page: 913
End page: 918
Abstract: PURPOSE: The purpose of the present phase II study was to evaluate both the efficacy and toxicity of the combination of S-1 and docetaxel in previously treated patients with locally advanced or metastatic non-small cell lung cancer. METHODS: Thirty-eight previously treated patients with non-small cell lung cancer were treated with S-1 (80 mg/m(2), days 1-14, oral) and docetaxel (40 mg/m(2), day 1, intravenous) every 3 weeks. RESULTS: No complete response was observed, and seven patients had a partial response, yielding an overall response rate of 18.4% (95% CI, 7.7-34.3%). The median overall survival time and 1-year overall survival rate were 16.1 months and 60%, respectively. The median progression-free survival time was 4.4 months. Myelosuppression was the main toxicity with grade 3 or 4 neutropenia and leukopenia in 50 and 21%, respectively. There was no irreversible toxicity in this study. CONCLUSIONS: The combination of S-1 and docetaxel is well tolerable and has substantial activity for patients with locally advanced or metastatic non-small cell lung cancer. A phase III trial comparing docetaxel with or without S-1 would warrant further investigation.
Rights: The original publication is available at www.springerlink.com
この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。This is not the published version. Please cite only the published version.
URI: http://hdl.handle.net/2433/129639
DOI(Published Version): 10.1007/s00280-009-1239-7
PubMed ID: 20069422
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.